Brief: Nextcure Presents Preclinical Data On A Novel Therapeutic Candidate Targeting Vstm-1
Brief: NextCure Publishes Non-Clinical Data Defining The Mechanism Of Action For NC525, A Novel LAIR-1 Antibody For AML
NextCure Inc reports results for the quarter ended in September - Earnings Summary
Brief: NextCure Q3 Net Income USD -14.301 Million
NextCure Inc expected to post a loss of 66 cents a share - Earnings Preview
Brief: NextCure Says Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta
Brief: NextCure Provides Update On Phase 2 Study Of Anti-Siglec-15 Antibody NC318
Brief: Nextcure Inc Files For Mixed Shelf Of Up To $180 Million – SEC Filing
NextCure Inc reports results for the quarter ended in June - Earnings Summary
NextCure Inc expected to post a loss of 59 cents a share - Earnings Preview
Brief: NextCure Presents Non-Clinical Data Defining Mechanism Of NC525
NextCure Inc reports results for the quarter ended in March - Earnings Summary
NextCure Inc expected to post a loss of 62 cents a share - Earnings Preview
NextCure Inc reports results for the quarter ended in December - Earnings Summary
Brief: Nextcure Provides Business Update And Reports Full Year 2022 Financial Results
NextCure Inc expected to post a loss of 66 cents a share - Earnings Preview
Brief: NextCure And LegoChem Biosciences Enter Into Collaboration
Brief: Nextcure Presents Initial Data From Clinical Trial Of Nc762 And A Trial In Progress Poster For Nc410 Combo
NextCure Inc reports results for the quarter ended in September - Earnings Summary